NCT02783833View on ClinicalTrials.gov

MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

January 16, 2017

Study Completion Date

January 16, 2017

Conditions
Malaria
Interventions
DRUG

MMV390048 40mg

DRUG

MMV390048 dose to be determined mg

Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.

Trial Locations (1)

4006

Q-Pharm Clinics, Herston

Sponsors
All Listed Sponsors
collaborator

Clinical Network Services (CNS) Pty Ltd

INDUSTRY

collaborator

Q-Pharm Pty Limited

INDUSTRY

collaborator

QIMR Berghofer Medical Research Institute

OTHER

lead

Medicines for Malaria Venture

OTHER

NCT02783833 - MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B | Biotech Hunter | Biotech Hunter